These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 884390)

  • 21. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
    Grange S; Holford NH; Guentert TW
    Pharm Res; 2001 Aug; 18(8):1174-84. PubMed ID: 11587490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voluntary drinking of ethanol by the rat: biogenic amines and possible underlying mechanism.
    Messiha FS
    Pharmacol Biochem Behav; 1978 Sep; 9(3):379-84. PubMed ID: 714986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lupus-like autoimmune syndrome after levodopa and benserazide.
    Massarotti G; Cassi E; Passaleva A
    Br Med J; 1979 Sep; 2(6189):553. PubMed ID: 497698
    [No Abstract]   [Full Text] [Related]  

  • 25. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
    Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
    Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
    [No Abstract]   [Full Text] [Related]  

  • 27. Modification of mouse liver alcohol and aldehyde-dehydrogenase by chlorpromazine.
    Messiha FS; Striegler RL; Sproat HF
    Drug Chem Toxicol; 1983; 6(5):409-19. PubMed ID: 6354684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 30. A structure activity relationship study on the effects of L-dopa and some metabolites on voluntary intake of ethanol solution by the rat.
    Messiha FS
    Proc West Pharmacol Soc; 1978; 21():271-5. PubMed ID: 693507
    [No Abstract]   [Full Text] [Related]  

  • 31. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
    [No Abstract]   [Full Text] [Related]  

  • 33. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues.
    Lyles GA; Callingham BA
    Biochem Pharmacol; 1982 Apr; 31(7):1417-24. PubMed ID: 7092930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man].
    Balestreri R; Bertolini S; Elicio N; Costa S
    Boll Soc Ital Biol Sper; 1974 Jul; 50(12):832-7. PubMed ID: 4447697
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
    Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.